Home > Oncology > ASCO 2020 > Gastrointestinal Cancer > REGOMUNE: a phase 2 study combining regorafenib and avelumab

REGOMUNE: a phase 2 study combining regorafenib and avelumab

Dr Sophie Cousin, Institut Bergonié, France
ASCO 2020
Phase 1/2, REGOMUNE
In REGOMUNE, the combination of regorafenib plus avelumab demonstrated progression-free survival (PFS) and overall survival (OS) results that compared favourably with historical data of regorafenib alone in patients with non-microsatellite-instability(MSI)-high metastatic colorectal cancer (mCRC). A composite score reflecting immune response of patients could be used as a biomarker in further studies to identify those who are more likely to benefit from the treatment. The tyrosine kinase inhibitor regorafenib is approved for the management of mCRC patients who have failed standard therapy. It has been shown to reduce immunosuppressive tumour-associated macrophages (TAMs) and to synergize with anti-PD1 inhibition in a preclinical model of microsatellite-stable CRC [1,2]. REGOMUNE is a phase 1/2 study evaluating the efficacy and safety of the combination regorafenib and avelumab, an anti-PDL1 antibody, in solid tumours [3]. In Cohort A, 48 patients wi...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on